# US 7,465,585 B1 · Compositions and methods for inhibiting cell migration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,465,585 B1
- Document ID: US7465585B1
- Status: Granted
- Kind: B1
- Application number: 11/786,146
- Filed: 2007-04-10
- Granted: 2008-12-16
- Earliest claimed: 2006-04-10
- Assignees: The Burnham Institute
- Inventors: Mark Mercola; Ruchika Gupta
- Web page: https://patentgrep.com/patent/US7465585B1

## CPC

- A61K 38/1709: {from mammals}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.

## Claims

### Claim 1

A method of mobilizing cells comprising contacting the cells with an effective amount of a fragment of Dickkopf-1 (Dkk1) protein of the formula: set forth in SEQ ID NO:4.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cells express endogenous Dkk1.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cells do not express endogenous Dkk1 protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cells contacted with the fragment migrate to the site of a wound.

### Claim 5

A method of mobilizing cells comprising contacting the cells with an effective amount of human Dickkopf-1 (Dkk1) protein set forth as SEQ ID NO:5 comprising a mutation in the amino terminal cysteine rich domain (CRD) and a mutation in the carboxy-terminal CRD.

### Claim 6 (depends on 5)

The method of claim 5, wherein the Dkk1 protein comprises a mutation at residues 124 and 194.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Dkk1 protein comprises aspartate at residue 124 and alanine at residue 194.

### Claim 8 (depends on 5)

The method of claim 5, wherein the cells do not express endogenous Dkk1 protein.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cells contacted with the Dkk1 protein migrate to the site of a wound.